Diagnostic and prognostic potential of the oral and gut microbiome for lung adenocarcinoma

Abstract

Dear Editor, Lung cancer is one of the most common cancers.1 Although its primary risk factor is smoking,2 15–20% and >50% of male and female lung cancer patients, respectively, are nonsmokers,3, 4 which indicates the involvement of other risk factors. Recently, alteration of the oral and gut microbiomes was observed in lung cancer patients,5, 6 suggesting potential roles of microbiota in lung cancer. We investigated the oral and gut microbiomes of never-smoking lung adenocarcinoma patients to identify microbial signatures of lung cancer, which can be used for diagnosis and prognosis. Oral and gut microbiomes were profiled from never-smoking lung adenocarcinoma patients (cancer, n = 91) and from age- and sex-matched never-smoking healthy controls (control, n = 91). Most patients were female (n = 84, 92.3%) and had stage IV lung cancer (n = 81, 89.0%; Table S1). Shannon's diversity index of the oral microbiome was significantly lower in patients, and the overall oral microbiome structure differed significantly between patients and controls (Figure 1A). The gut microbiome structure also differed between patients and controls, but the difference in Shannon diversity was insignificant (Figure S1A). The patients were further categorized into treated (Treatment+, n = 52) and untreated groups (Treatment–, n = 39) based on, at the time of microbiome sampling, whether they had received one or more lines of chemotherapy or targeted drug therapy for lung cancer since their first lung cancer diagnosis. The oral microbiome diversity was reduced in the Treatment– group (Wilcoxon rank-sum, p = 0.21) and reduced more in the Treatment+ group (Wilcoxon rank-sum, p = 0.01; Figure 1B). No significant difference in the gut microbiome diversity was observed irrespective of treatment status (Figure S1B). Regardless of the oral and gut microbiomes, the samples in the Treatment– and Treatment+ groups were located closer to each other on the principal coordinate analysis plot than to the control samples (Figure 1B and Figure S1B). We further compared the relative abundance of genera in the oral microbiome of the patients and controls. Veillonella was more abundant in the patients, whereas the abundance of 15 genera—Mogibacterium, Butyrivibrio, Variovorax, Ralstonia, Catonella, Bulleidia, and Oribacterium—decreased in the patients (Wilcoxon rank-sum test, false discovery rate [FDR] < 0.1; Figure 2A). These seven genera were significantly less abundant in the patients regardless of treatment history (Figure 2B,C). By contrast, some taxa were associated with the treatment condition: Olsenella was more abundant in the Treatment+ patients, whereas Veillonella was more abundant in the Treatment– patients (Figure 2B,C). Compared with oral bacteria, a relatively small number of gut bacterial taxa was associated with lung cancer. Clostridium, Enterococcus, and Streptococcus were enriched in patients, whereas Faecalibacterium was enriched in controls (Wilcoxon rank-sum test, FDR < 0.1; Figure S2A). A similar difference was observed between the Treatment+ and control groups, but not between the Treatment– and control groups (Figure S2B). Considering that microbes in the oral cavity can potentially migrate to the lungs,7 they may be more strongly associated with lung cancer than gut microbes. Although the functions of lung cancer–associated microbes are not clearly understood, there are some references about them. Veillonella can activate cancer signaling pathways in airway epithelial cells,8 and the enrichment of Enterococcus and Streptococcus in the gut microbiome is linked to colorectal cancer.9 Faecalibacterium can modulate systemic immune responses.10 We further discussed the functional implications of these microbes in the Supporting Information. We then evaluated whether the cancer status can be predicted from oral microbiome profiles. The patients were successfully distinguished from the controls using a machine learning model, with an area under the receiver operating characteristic curve (AUC) of 0.95 in the fivefold cross-validation tests (Figure 3A and Figure S3). We further confirmed the performance of predictive models on an independent dataset including 41 patients with nonsmall cell lung carcinoma and 612 healthy controls (AUC = 0.88). The predictive model trained with the control and Treatment+ groups could distinguish cancer status (AUC = 0.96) better than the model trained with the control and Treatment– groups (AUC = 0.88; Figure 3A). The predictive performance on the independent dataset was also higher for the model trained with the Treatment+ group (AUC = 0.86) than that with the Treatment– group (AUC = 0.80). Although the prediction performance slightly varied, a similar set of microbial taxa was used in the two models (Figure 3B). Hence, the oral microbial taxa identified herein represent a general signature of lung cancer and can be used as diagnostic biomarkers. Cancer status could also be predicted using gut microbiome profiles, but its predictive power was limited (AUC = 0.76; Figure S4A); the performance on the independent dataset was lower (AUC = 0.67). The gut microbiome of the Treatment+ group was slightly more informative in predicting the cancer status than that of the Treatment– group (Figure S4A). Similar genera were used in both models (Figure S4B), and their performances on the independent dataset were similar (AUC = 0.67, for both models, respectively). To evaluate the prognostic impact of microbiome profiles, we clustered the patients into two groups by their oral microbiome similarity (Figure 4A). For the overall microbial structure, the first group (Cluster 1) was more dissimilar from the controls than the second group (Cluster 2; Figure 4B). In the Treatment– group, although statistical significance was not achieved, Cluster 2 patients had a trend toward longer survival than Cluster 1 patients (p = 0.14; Figure 4C). Streptococcus and Megasphaera were more abundant and Haemophilus was less abundant in the group with a worse survival outcome (Cluster 1; Figure 4D,E). However, no significant difference was observed in survival outcome among the Treatment+ patients. Collectively, we found the alterations in the oral and gut microbiomes associated with lung adenocarcinoma and cancer treatment. The predictive models based on oral microbiome profiles could successfully distinguish the lung cancer patients from the healthy controls. These findings suggest the possibility of diagnosis of lung cancer, especially for nonsmokers, using oral microbiome profiles. This work was supported by the Main Research Program (grant number E0170600-05) of the Korea Food Research Institute (KFRI) funded by the Ministry of Science and ICT, and by the National Cancer Center (grant number 1910280). The authors declare no conflict of interest. This study was performed with approval from the National Cancer Center Institutional Review Board (approval number NCC2016-0208). All the participants provided written informed consent. The oral and gut microbiome data of never-smoking patients with lung adenocarcinoma are available in the European Nucleotide Archive (https://www.ebi.ac.uk/ena/) under accession numbers PRJEB44168 and PRJEB44169, respectively. Ji-Youn Han and Young-Do Nam conceived and designed the study. Kum Hui Hwang, Eun Jin Lim, and Ji-Youn Han collected the patients’ samples and provided the clinical information. Mi Young Lim performed the experiments. Mi Young Lim and Seungpyo Hong analyzed the data and wrote the manuscript. All authors reviewed the manuscript. The authors read and approved the final manuscript. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.

Topics & Concepts